Seaport Therapeutics, Inc. Common Stock Total Assets
Seaport Therapeutics, Inc. Common Stock total assets. Based on the latest financial reports, Seaport Therapeutics, Inc. Common Stock (SPTX) holds total assets worth $441.68 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Seaport Therapeutics, Inc. Common Stock market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Seaport Therapeutics, Inc. Common Stock (2024–2025)
Total assets of Seaport Therapeutics, Inc. Common Stock from 2024 to 2025. This chart illustrates how Seaport Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See Seaport Therapeutics, Inc. Common Stock stock price for real-time trading data and today's change.
Seaport Therapeutics, Inc. Common Stock - Asset Composition Analysis
Seaport Therapeutics, Inc. Common Stock Total Assets Breakdown (December 2025)
Seaport Therapeutics, Inc. Common Stock total assets breakdown as of December 2025. Seaport Therapeutics, Inc. Common Stock's total assets of $441.68 Million consist of 89.7% current assets and 10.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 18.5% |
| Accounts Receivable | $3.03 Million | 1.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2024–2025)
This chart illustrates how Seaport Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore SPTX working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Seaport Therapeutics, Inc. Common Stock's current assets represent 89.7% of total assets in 2025, a decrease from 98.2% in 2024.
- Cash Position: Cash and equivalents constituted 18.5% of total assets in 2025, down from 97.9% in 2024.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2024.
- Asset Diversification: The largest asset category is accounts receivable at 1.2% of total assets.
Seaport Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of Seaport Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Seaport Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 18.00 | 13.24 | - |
| Quick Ratio | 18.00 | 13.24 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | $266.50 Million | $174.12 Million | - |
Seaport Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Seaport Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.97 |
| Latest Market Cap to Assets Ratio | 4.51 |
| Asset Growth Rate (YoY) | -21.1% |
| Total Assets | $249.01 Million |
| Market Capitalization | $1.12 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Seaport Therapeutics, Inc. Common Stock's assets at a significant premium (4.51x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Seaport Therapeutics, Inc. Common Stock's assets decreased by 21.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Seaport Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual total assets of Seaport Therapeutics, Inc. Common Stock from 2024 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $249.01 Million | -21.14% |
| 2024-12-31 | $315.78 Million | -- |
About Seaport Therapeutics, Inc. Common Stock
Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-30… Read more